What Is GCKR? Gene, Protein Structure, and Biological Role

The glucokinase regulatory protein (GCKR), encoded by the GCKR gene located on chromosome 2p23.3 in humans, is a member of the bacterial sugar isomerase (SIS) domain superfamily. It functions as an endogenous inhibitor of glucokinase (hexokinase IV, GCK), a rate-limiting enzyme in hepatic glucose metabolism responsible for phosphorylating glucose to glucose-6-phosphate.

GCKR exerts its regulatory effect by forming a non-covalent complex with GCK, sequestering the enzyme in the hepatocyte nucleus when fasting glucose concentrations are low. Upon postprandial elevation of blood glucose or exposure to fructose-1-phosphate (F1P), GCKR releases GCK into the cytoplasm, where it is free to phosphorylate glucose. This nucleus-cytoplasm shuttling mechanism provides a rapid and reversible means of controlling hepatic glucose uptake and glycolysis.

GCKR also responds to the allosteric effector fructose-6-phosphate (F6P), which promotes GCKR–GCK complex formation and nuclear sequestration, counterbalancing F1P's dissociating effect. This dual-ligand switch makes GCKR a sophisticated metabolic sensor integral to postprandial glucose homeostasis.

GCKR in Disease: Genetic Variants and Clinical Significance

Genome-wide association studies (GWAS) have identified the GCKR locus as one of the most replicated genetic determinants of fasting plasma triglycerides, glucose, and insulin levels. The common missense variant rs1260326 (p.Pro446Leu) reduces GCKR's inhibitory capacity, resulting in increased GCK activity, enhanced hepatic glucose uptake, and elevated flux into lipogenic pathways, ultimately raising circulating triglyceride levels while paradoxically lowering fasting glucose.

This metabolic trade-off positions GCKR variants as important contributors to:

• Type 2 diabetes mellitus (T2DM): Altered GCK activity affects insulin secretion signaling thresholds and hepatic glucose output.
• Hypertriglyceridemia and dyslipidemia: Enhanced de novo lipogenesis driven by excess glucose-6-phosphate.
• Nonalcoholic fatty liver disease (NAFLD): Increased hepatic lipid accumulation downstream of elevated glycolytic flux.
• Chronic kidney disease: Epidemiological associations have been reported, though mechanisms remain under investigation.

Understanding GCKR protein function at the biochemical level is therefore crucial for drug discovery programs targeting metabolic syndrome and for interpreting genetic epidemiology data.

Research Applications of Recombinant Human GCKR Protein

Recombinant Human GCKR Protein (SKU: rp367933) supports a broad range of in vitro research workflows:

• Enzyme activity and inhibition assays: GCKR can be used to reconstitute GCK–GCKR complexes in vitro, enabling quantitative measurement of GCK inhibition kinetics and dose-response studies with potential activators or disruptors.
• Protein–protein interaction (PPI) studies: As the canonical GCK binding partner, recombinant GCKR serves as bait or prey in pull-down assays, surface plasmon resonance (SPR), bio-layer interferometry (BLI), and co-immunoprecipitation experiments to characterize binding affinity and stoichiometry.
• Structural biology: High-purity recombinant GCKR is suitable for X-ray crystallography, cryo-electron microscopy (cryo-EM), and small-angle X-ray scattering (SAXS) studies aimed at resolving GCK–GCKR complex conformation under different ligand conditions.
• Drug discovery and screening: GCKR is a target of interest for small-molecule programs seeking to modulate GCK activity indirectly; recombinant protein enables high-throughput compound screening and structure-activity relationship (SAR) studies.
• Biomarker and antibody development: Recombinant GCKR provides an antigen standard for ELISA development, antibody validation, and immunoassay calibration.

Researchers should confirm specific activity, purity, and formulation details on the product datasheet prior to experimental use.

Handling, Storage, and Quality Considerations

Proper handling of recombinant proteins is essential to preserve biological activity and experimental reproducibility. The following general best-practice guidelines apply to Recombinant Human GCKR Protein; always defer to the product-specific datasheet for definitive instructions:

• Storage temperature: Recombinant proteins are typically stored at −80 °C for long-term preservation. Avoid repeated freeze-thaw cycles, which can cause aggregation and loss of activity.
• Aliquoting: Upon first thaw, divide into single-use aliquots to minimize freeze-thaw stress.
• Carrier protein: Many recombinant protein formulations include bovine serum albumin (BSA) or glycerol as stabilizers; verify whether the specific lot formulation is compatible with your downstream assay.
• Purity verification: Confirm purity by SDS-PAGE or SEC-HPLC data provided in the certificate of analysis (CoA). For activity-sensitive applications, confirm biological activity using a validated GCK inhibition or binding assay.
• Endotoxin levels: For cell-based assays, confirm that endotoxin levels (EU/mg) meet the threshold required to avoid confounding inflammatory responses.

Contact Aladdin Scientific technical support for lot-specific CoA documents, custom formulation requests, or application-specific recommendations.